EQL.ST EQL Pharma AB

Healthcare Drug Manufacturers - Specialty & Generic Stockholm Exchange
25.95 SEK
Close of Nov 7, 2026
17.38 67.50
Market cap
SEK 766M
P/E
865.0x
P/B
3.07x
ROE
-26.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is EQL.ST undervalued?

Graham number

The Graham number of EQL Pharma AB cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EQL Pharma AB fundamental analysis

No fundamental analysis for EQL Pharma AB yet.

EQL Pharma AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

Full company profile